+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Time Course of Serum Prolactin and Sex Hormones following Successful Renal Transplantation

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Background: Chronic renal failure is commonly associated with disturbances in hypothalamic-pituitary-gonadal function. Methods: The gonadotrophins, prolactin and estradiol or testosterone levels were measured immediately before renal transplantation, at discharge from the transplantation unit (19 ± 8 days after Tx) and 6 months after transplantation in 21 patients, 7 females and 14 males, age range 21–60 years. Results: The mean prolactin level was high during uremia and decreased rapidly after transplantation, from 441 to 167 mU/l in males and from 1,057 to 521 mU/l in females. Hypergonadotrophism was seen in most uremic patients, with the mean LH and FSH levels of 14.2 and 6.0 U/l in males and 14.7 and 4.0 U/l in females, respectively. A temporary change to hypogonadotrophic hypogonadism took place 2–3 weeks after transplantation and was followed by normalization of the hypothalamic-gonadal function. The levels of circulating sex steroids were suppressed when the patients were discharged from the transplantation unit but returned to the normal range at 6 months. Conclusions: We conclude that renal transplantation corrects the hyperprolactinemia induced by uremia and is followed by rapid onset of restoration of the hypothalamic-pituitary-gonadal axis.

          Related collections

          Author and article information

          S. Karger AG
          September 2002
          26 September 2002
          : 92
          : 3
          : 735-737
          aUniversity of Tampere, Medical School, and bTampere University Hospital, Tampere; cUniversity Hospital of Kuopio, and dUniversity Hospital of Helsinki, Finland
          64079 Nephron 2002;92:735–737
          © 2002 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Tables: 1, References: 7, Pages: 3
          Self URI (application/pdf): https://www.karger.com/Article/Pdf/64079
          Short Communication

          Cardiovascular Medicine, Nephrology

          Transplantation, Sex steroids, Renal failure, Hypogonadism


          Comment on this article